

# PRISMA 2020 Checklist

## with Network Meta-Analysis Extension

*Myopia Control Interventions in Children: A Network Meta-Analysis*

INPLASY202670068 · British Journal of Ophthalmology

| Section / Topic       | #   | Checklist Item                                                                         | Reported on Page # |
|-----------------------|-----|----------------------------------------------------------------------------------------|--------------------|
| <b>TITLE</b>          |     |                                                                                        |                    |
|                       | 1   | Identify the report as a systematic review.                                            | 1                  |
|                       |     |                                                                                        |                    |
| <b>ABSTRACT</b>       |     |                                                                                        |                    |
|                       | 2   | See the PRISMA 2020 for Abstracts checklist.                                           | 2                  |
|                       |     |                                                                                        |                    |
| <b>INTRODUCTION</b>   |     |                                                                                        |                    |
| Rationale             | 3   | Describe the rationale for the review in the context of existing knowledge.            | 2–3                |
| Objectives            | 4   | Provide an explicit statement of the objective(s) or question(s) the review addresses. | 3                  |
| NMA — Rationale       | S1  | Describe why a network meta-analysis was conducted.                                    | 2–3                |
| NMA — Objectives      | S2  | Describe the research questions based on the network of interventions (PICO).          | 3                  |
|                       |     |                                                                                        |                    |
| <b>METHODS</b>        |     |                                                                                        |                    |
| Eligibility criteria  | 5   | Specify inclusion/exclusion criteria and how studies were grouped for syntheses.       | 4                  |
| Information sources   | 6   | Specify all databases, registers, websites, and date last searched.                    | 3                  |
| Search strategy       | 7   | Present full search strategies for all databases, including filters and limits.        | 3 + Supplement     |
| Selection process     | 8   | Specify how reviewers screened records; number of reviewers, independence.             | 4                  |
| Data collection       | 9   | Specify how data were collected; number of reviewers, independence.                    | 4                  |
| Data items            | 10a | List and define all outcomes for which data were sought.                               | 4                  |
|                       | 10b | List all other variables (participant/intervention characteristics, funding).          | 4                  |
| Risk of bias          | 11  | Specify the tool(s) used to assess RoB and process.                                    | 4                  |
| Effect measures       | 12  | Specify effect measure(s) used (e.g. mean difference).                                 | 5                  |
| Synthesis methods     | 13a | Describe how studies were determined eligible for each synthesis.                      | 4                  |
|                       | 13b | Describe data preparation (handling missing data, data conversions).                   | 5                  |
|                       | 13c | Describe methods to tabulate/visually display results.                                 | 5                  |
|                       | 13d | Describe synthesis methods (model, heterogeneity, software).                           | 5                  |
|                       | 13e | Describe methods to explore heterogeneity (subgroup, meta-regression).                 | 5                  |
|                       | 13f | Describe sensitivity analyses to assess robustness.                                    | 5                  |
| NMA — Synthesis       | S3  | Describe NMA model (frequentist, random-effects), software (R).                        | 5                  |
| NMA — Inconsistency   | S4  | Describe methods to evaluate inconsistency and transitivity assumptions.               | 5                  |
| Reporting bias        | 14  | Describe methods to assess risk of bias due to missing results.                        | 5                  |
| Certainty assessment  | 15  | Describe methods to assess certainty/confidence in the evidence.                       | 5                  |
| NMA — Certainty       | S5  | Describe methods for certainty of NMA estimates.                                       | 5                  |
|                       |     |                                                                                        |                    |
| <b>RESULTS</b>        |     |                                                                                        |                    |
| Study selection       | 16a | Describe results of search and selection, ideally with flow diagram.                   | 5 + eFigure 1      |
|                       | 16b | Cite studies that appeared eligible but were excluded, with reasons.                   | 5–6 + Supplement   |
| Study characteristics | 17  | Cite each included study and present its characteristics.                              | 6 + Table 1        |
| RoB in studies        | 18  | Present RoB assessments for each included study.                                       | 6 + eFigure 2      |
| Individual results    | 19  | For all outcomes, present summary statistics and effect estimates with precision.      | 6, Tables 2–3      |
| Synthesis results     | 20a | Summarise characteristics and RoB among contributing studies.                          | 6                  |
|                       | 20b | Present all synthesis results: summary estimate, precision, heterogeneity.             | 6–7                |

|                       |     |                                                                            |                 |
|-----------------------|-----|----------------------------------------------------------------------------|-----------------|
|                       | 20c | Present results of heterogeneity investigations.                           | 7               |
|                       | 20d | Present results of sensitivity analyses.                                   | 7               |
| NMA — Geometry        | S6  | Present network structure: studies, comparisons, nodes, with network plot. | 6 + Figure 1    |
| NMA — Results         | S7  | Present NMA results: treatment effects, ranking (P-scores).                | 6–7, Tables 2–3 |
| NMA — Inconsistency   | S8  | Present inconsistency assessment results (global + local).                 | 7 + Supplement  |
| Reporting biases      | 21  | Present assessments of risk of bias due to missing results.                | 7 + eFigure 2   |
| Certainty of evidence | 22  | Present assessments of certainty/confidence in the evidence.               | 7               |
|                       |     |                                                                            |                 |
| <b>DISCUSSION</b>     |     |                                                                            |                 |
| Discussion            | 23a | General interpretation of results in context of other evidence.            | 7–8             |
|                       | 23b | Discuss limitations of the evidence included.                              | 8               |
|                       | 23c | Discuss limitations of the review processes used.                          | 8               |
|                       | 23d | Discuss implications for practice, policy, and future research.            | 8               |
|                       |     |                                                                            |                 |
| <b>OTHER INFO</b>     |     |                                                                            |                 |
| Registration          | 24a | Provide registration information (register name + number).                 | 1 (title page)  |
|                       | 24b | Indicate where the protocol can be accessed.                               | 3 (Methods 2.1) |
|                       | 24c | Describe and explain any protocol amendments.                              | 3               |
| Support               | 25  | Describe sources of financial/non-financial support and funder role.       | 9               |
| Competing interests   | 26  | Declare any competing interests of review authors.                         | 9               |
| Data & code           | 27  | Report which materials are publicly available (data, code, forms).         | 9               |
| NMA — Data & code     | S9  | Report where NMA data and analytic code can be accessed.                   | 9               |

*This checklist incorporates PRISMA 2020 standard items and the PRISMA NMA Extension (S1–S9). Sources: Page MJ, et al. BMJ 2021;372:n71. Hutton B, et al. Ann Intern Med 2015;162:777-784.*

*Page numbers refer to page numbers in the main manuscript file (Title Page = Page 1). "eFigure / Supplement" indicates content in the Supplementary Materials. Verify page numbers against the final formatted manuscript before submission.*

*PRISMA website: <http://www.prisma-statement.org/>*